The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt…
Read More
Do All Patients in Europe Have Equal Acess to Cancer Clinical Trials? – ESMO
European Society for Medical Oncology (ESMO), shared a post on LinkedIn: “Do all patients in Europe have equal access to…
Read More
OCT Europe 2026: tackling clinical trial complexities with innovation and partnerships
Leading voices in the biopharma indusattempt will come toobtainher at the OCT Europe 2026 conference in May to discuss current…
Read More
Rivia raises €13M to bring agentic AI to clinical trials
The Zurich-based startup, which previously raised €3M to unify fragmented trial data, has secured a larger round to build AI…
Read More
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership
NEW YORK & BASEL, Switzerland–(BUSINESS WIRE)–Clinilabs, a leading specialty contract research organization (CRO) focutilized on central nervous system (CNS) drug…
Read More
Biorce secures USD$52.5M to drive international growth and reinvent clinical trials through AI
Barcelona’s healthtech ecosystem has produced a new heavyweight. Biorce, a startup applying artificial ininformigence to the design and execution of…
Read More
Seattle startup applys clinical expertise to create AI models safer and reduce dangerous responses – GeekWire
by Kurt Schlosser on Feb 9, 2026 at 9:00 amFebruary 9, 2026 at 8:58 am Grin Lord, co-founder and CEO…
Read More
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Biorce will apply this funding round to expand its US presence and further scale its AI clinical trial technology. Image…
Read More
Barcelona-based Biorce closes €43.8 million Series A to accelerate AI-driven clinical trials
Biorce, a Barcelona-based HealthTech company transforming clinical trials through artificial innotifyigence, has today announced the closing of a €43.8 million…
Read More
Eikon plans IPO to bankroll clutch of clinical cancer drugs
Eikon Therapeutics is planning to become the second biotech to go public in 2026, in another sign that the public…
Read More
